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Abstract: Tumor stroma interaction is known to take a crucial role in cancer growth and progression. In the present study, it was performed gene expression analysis of stroma samples with ovarian and breast cancer through an integrative analysis framework to identify
common critical biomolecules at multiomics levels. Gene expression datasets were statistically analyzed to identify common differentially expressed genes (DEGs) by comparing tumor stroma and normal stroma samples. The integrative analyses of DEGs indicated
that there were 59 common core genes, which might be feasible to be potential marks for cancer stroma targeted strategies. Reporter
molecules (i.e. receptor, transcription factors and miRNAs) were determined through a statistical test employing the hypergeometric
probability density function. Afterward, the tumor microenvironment protein-protein interaction and the generic network were reconstructed by using identified reporter molecules and common core DEGs. Through a systems medicine approach, it was determined that
hub biomolecules, AR, GATA2, miR-124, TOR1AIP1, ESR1, EGFR, STAT1, miR-192, GATA3, COL1A1, in tumor microenvironment
generic network. These molecules were also identified as prognostic signatures in breast and ovarian tumor samples via survival analysis. According to literature searching, GATA2 and TORYAIP1 might represent potential biomarkers and candidate drug targets for the
stroma targeted cancer therapy applications.
Key words: Gene expression, cancer stroma, biomarkers, network medicine

1. Introduction
Stroma is a mass of connective tissue that surrounds a
set of cells formed by the elements involved in an organ
or formation. Cancer is a disease involving multiple
components of both tumor cells and stromal cells (Mao
et al., 2013). Stromal cells participate in all steps of tumor
initiation, progression, recurrence, metastasis and drug
response, and finally, affect the prognosis of patients (Guo
and Deng, 2018). Stromal cells in the microenvironment
of the tumor have been shown to play an important role
in cancer development. Molecular events in which active
stromal cells affect cancer cells can be determined so
that biomarkers and therapeutic targets can be identified
(Valkenburg et al., 2018). Breast cancer is usually seen
in the breast epithelium, but there is some important
evidence that breast stromal cells also play an important
role in tumor formation (Mao et al., 2013). Ovarian cancer,
which proceeds from cell transformation through normal
tissue invasion, is also connected to communication with
the stromal microenvironment (Schauer et al., 2011). Both
tumor types have common molecular characteristics. For

example, BRCA1 and BRCA2 are common susceptibility
genes for breast and ovarian cancer (King et al., 2003).
Advances in microarray and high-throughput
sequencing technologies have provided effective
applications to help develop more reliable biomarkers
for diagnosis, survival and prognosis (Gov et al., 2017a).
The predictive power of a single gene biomarker may
be insufficient. The resulting studies have found that
gene signatures, including several genes, may be better
alternatives. The functions and mechanisms of gene
signatures in diseases continue to be explored further. In
several studies, the identification of molecular signatures
to understand disease mechanism and explore the drug
targets was studied such as key genes of three different
ovarian diseases by using integrative systems biology
analysis perspective (Kori et al., 2016), tissue-specific
molecular biomolecules in ovarian cancer (Gov et al.,
2017b), T2 diabetes (Calimlioglu et al., 2015), head and
neck cancer (Islam et al., 2018) and Alzheimer disease
(Rahman et al., 2020), as well as ovarian cancer stem cells
(Gov, 2020).
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Cancer tissues produce special stroma, preferably for
abnormal proliferation and invasion. Some other types
of cells, such as fibroblasts, preexisting vascular cells,
and mesenchymal stem cells, become potentially cancerrelated fibroblasts (CAFs). Significant proinflammatory
factors expressed by CAFs have been reported in some
types of cancer such as breast and ovarian cancer (Erez
et al., 2013). It was reported that infiltrated immune
and inflammatory cells affect the molecular biology and
clinical status of breast cancer (Karn et al., 2015). Planche
et al. (2011) reported that the tumor microenvironment
displays distinct features according to the cancer type that
has prognostic predictive potentials in a study about the
identification of common molecular signatures of breast
and prostate tumor stroma.
In the present study, we performed an analysis of
transcriptome datasets of ovarian cancer stroma and
breast cancer stroma through an integrative systems
biology perspective to identify common critical molecular
signatures at multiomics levels. This study represents
mutual reporter molecules for ovarian and breast cancer
stroma as a potential prognostic molecular signatures
and may provide a contribution about common cancer
stroma response map for cancer treatment, diagnosis and
prognosis.
2. Materials and methods
2.1. Selection of the gene expression datasets
The raw data of three transcriptome datasets related to
breast cancer stroma [GSE26910 (Planche et al., 2011),
GSE8977 (Karnoub et al., 2007) and GSE10797 (Casey
et al., 2009)] and two datasets related to ovarian cancer
stroma [GSE40595 (Yeung et al., 2013) and GSE38666 (Lili
et al., 2013)] are obtained from Gene Expression Omnibus
(GEO) (Barrett et al., 2013). The datasets originated from
Affymetrix Human Genome U133 Plus 2.0 Array were
selected. Samples of datasets were obtained from tumor
stroma and normal stroma. A total of 79 tumor stroma and
43 normal stroma including 41 breast tumor stroma vs. 27
normal breast stroma and 38 ovarian tumor stroma vs.16
normal ovarian stroma were studied.
2.2. Identification of differentially expressed genes
For identification of differentially expressed genes (DEG),
CEL microarray raw data files were downloaded and affy
package (Gautier et al., 2004) of the R (version 3.6) was
employed. The executed dataset was normalized through
robust multiarray (RMA) techniques (Bolstad et al., 2003)
and linear models for microarray data (LIMMA) method
(Smyth et al., 2003) were examined in the advanced
statistical analysis of each dataset. DEGs were determined
according to resultant p-values < 0.05 and fold changes
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were taken into account to determine the regulatory
patterns of the DEGs (fold change >1.5 and <0.67).
2.3. Gene enrichment analysis of gene sets
Gene enrichment analysis was carried out via the
ConsensusPathDB functional annotation tool (Kamburov
et al., 2013) to determine the down and upregulated
biological pathways statistically significant associated
with DEGs. Reactome (Croft et al., 2011) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa
et al., 2012) were preferable used databases and enrichment
results with a p-value of <0.01 were accepted. Each p-value
is calculated utilizing the hypergeometric test for each of
the biological pathways. The whole genome description
and background for the human genome were utilized as
the reference gene set.
2.4. Protein-protein interaction network reconstruction
The previously reconstructed comprehensive proteinprotein interaction (PPI) network of Homo sapiens
(Karagoz et al., 2016) which consists of 288,033 physical
interactions between 21,052 proteins, was utilized. Cancer
stroma-specific PPI network was reconstructed using
the proteins encoded by the resultant core DEGs. In PPI
networks, nodes represent proteins and edges represent
interaction which is accepted as undirected between
proteins. The networks were analyzed and visualized
through Cytoscape (v3.6) (Smoot et al., 2011). To identify
highly connected central proteins (i.e. hub protein) of PPI
networks the dual-metric approach considering degree
and betweenness centrality metrics simultaneously was
used (Gov et al., 2017b).
2.5. Identification of reporter molecules
To identify reporter molecules firstly interaction data
were arranged. Interaction data were obtained from our
previous study (Comertpay and Gov, 2020) consisting of
284 TFs, 2599 miRNAs, 916 receptors and 22808 genes.
Reporter molecules were determined via employing the
hypergeometric probability density function by using
the physical interaction of TFs, miRNAs and receptors
with core DEGs obtained from breast and ovarian cancer
stroma datasets.
The adopted our procedure (Comertpay and Gov,
2020) was applied to gene expression data of cancer stroma
and employed in the prediction of molecular signature in
the tumor microenvironment. Reporter molecules were
identified according to computed p-values < 0.05.
2.6. Tumor microenvironment generic network
reconstruction
The reconstruction of stroma specific network was
employed by using reporter receptors, regulatory reporter
molecules, TFs and miRNAs, interacted with target
core DEGs. The visualization of network was provided
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via Cytoscape (v3.6) which is an open-source software
platform (Smoot et al., 2011).
2.7. Prognostic performance analysis
Cox survival analysis was performed to determine the
prognostic performance of the hub genes in the tumor
microenvironment generic network using comprehensive
microarray and RNA-Seq datasets. In the analyses, breast
cancer dataset (n = 962) from TCGA and ovarian cancer
dataset (n = 329) from TCGA and ICGC databases were
employed. Cox proportional hazards regression analysis
was executed through the SurvExpress validation tool
(Aguirre-Gamboa et al., 2013). In SurvExpress, the cancer
samples were grouped into low- and high-risk groups
according to their prognostic index calculated using patient
survival times. The prognostic capabilities of the hub genes
were identified through Kaplan–Meier plots and the logrank test. Furthermore, heat map representation was used
to the gene expression pattern of hub genes according to
low- and high-risk groups and the p-value was obtained
from the Student’s t-test.
Cox-survival analysis of hub miRNAs was performed
by using the Kaplan–Meier plotter tool (Nagy et al., 2018).
In the pan-cancer section, breast cancer (n = 1077) and
ovarian cancer (n = 486) datasets were used for drawing of
Kaplan–Meier plots.
3. Results
3.1. Mutual tumor microenvironment signatures for
breast and ovarian cancer
The microarray datasets obtained from the stroma of
breast and ovarian cancer were analyzed. For both cancer
stroma gene expression analyses, it was determined that
the number of the downregulated genes is a little higher
than the upregulated genes number except GSE40595
(Figure 1a). The integrative analyses of DEGs indicated that
there were 59 mutual core DEGs were identified between
the five datasets (Figure 1b). These core DEGs were
considered as mutual tumor stroma signatures for breast
and ovarian cancer. The genes were classified according
to their molecular functions and biological processes. It
was determined prominent biological processes like the
cellular process (45.7%), metabolic process (30%) and
biological regulation (25.4%) (Figure 1c) and molecular
activities as binding (39%), catalytic activity (18.6%)
(Figure 1d). PANTHER GO-slim analysis showed that the
core DEGs were enriched in different biological processes
and molecular functions.
The biological pathway enrichment analysis of each
dataset revealed that common pathways in immune systems
related pathways (37.5%), signaling pathways (29%), and
stroma associated pathways such as proteoglycan in cancer,

collagen formation, extracellular matrix organizations
were altered (Figure 2). It was determined that common
pathways mostly upregulated (green colors in Figure 2)
while PKA activation is downregulated in four datasets.
Common enriched pathways of GSE10792 is low due to it
has few number of DEGs compared to other datasets.
3.2. Tumor microenvironment protein interaction
network
The first neighbor enriched PPI network of the proteins
of corresponding mutual core DEGs was constructed
including 907 nodes and 1660 edges. Tumor stroma
specific PPI network represented scale-free topology
with a few highly-connected proteins. The hub proteins
including EGFR, STAT1, VDR, NCOA1, CTBP2, MET,
EIF3B, LEF1, KIF1B and CIRBP were identified by using
degree (local-based) and betweenness centrality (globalbased) metrics (Kori et al., 2016).
3.3. Tumor microenvironment generic network with
enriched reporter biomolecules
To identify common breast and ovarian cancer stroma
response map was constructed using core DEGs and
reporter biomolecules. According to hypergeometric
probability analysis results, 7, 12 and 32 reporter receptors,
TFs and miRNAs significantly interacted with core DEGs
were identified (p < 0.01), respectively (Table 1). The
results have been mapped by using core DEGs reporter
biomolecules interaction and it was reconstructed tumor
microenvironment generic network of breast and ovarian
cancer including 105 nodes and 251 edges (Figure 3).
Through topological analysis, hub biomolecules (AR,
COL1A1, EGFR, ESR1, GATA2, GATA3, miR-124-3p,
miR-192-5p, STAT1 and TOR1AIP1) were identified.
Interestingly, COL1A1 and TOR1AIP1 which are mutual
core DEGs were determined as highly connected with
reporter biomolecules. On the other hand, EGFR and
STAT1 are both core DEGs and hub proteins in the PPI
network. The rest of the reporter biomolecules are TFs
and miRNAs having transcriptional regulatory and
posttranscriptional regulatory functions.
From a generic network, it was revealed resultant
reporter biomolecules interact within themselves. We
obtain some of the scenarios (Figure 4) such as regulatory
biomolecules GATA2 and miR-124-3p interacted with
COL1A1 (Figure 4a). It was determined the interaction of
AR, GATA3 as a reporter TFs and EGFR which is both a
hub protein in the PPI and a core DEG (Figure 4b). In the
other interesting scenario, TOR1AIP1 interacts with ESR1,
GATA2, GATA3 which are reporter TFs and miR-192-5p
(Figure 4c). Similarly, ESR1, GATA2 and GATA3 interact
with STAT1 which is both a hub protein in the PPI and a
core DEG (Figure 4d). Table 2 represents description of
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Figure 1. Differentially expressed genes (DEGs) in breast and ovarian tumor stroma. a) The distribution of DEGs in
stromal cells of breast and ovarian cancer. Downregulation and upregulation of DEGs were represented by orange
and blue colors, respectively. b) Venn diagram representation for the comparison of DEGs among stromal cells of
breast and ovarian cancer. Core DEGs in all samples. c) PANTHER classification of core DEGs according to their
biological process. d) PANTHER classification of core DEGs according to their molecular function.

Figure 2. Statistically significant biological pathways in each datasets containing breast and ovarian cancer stroma samples. Downand upregulated gene list of each dataset was used to obtain down- and up-egulated pathways. Downregulation and upregulation of
pathways were represented by pink and green colors, respectively. Both up- and downregulated pathways were represented by grey color.

130

ERCEYLAN et al. / Turk J Biol
Table 1. Reporter molecules in the mutual tumor stroma of breast and
ovarian cancer.
p-value
miR-192-5p

Reporter TFs p-value

3.00E-05 AR

Reporter
p-value
receptors

2.17E-07 BMX

0.0032

miR-124-3p

4.50E-05 ESR1

9.35E-05 CCR5

0.0038

miR-33b-3p

0.0001

0.0055

0.0006

GATA2

EP300

miR-519e-3p

0.0002

GATA3

0.0002

LCK

0.0052

miR-515-3p

0.0002

MYF6

0.0025

MTOR

0.0007

miR-145-5p

0.0002

MYOD1

0.0025

NCOA2

0.0097

PTPRJ

0.004

miR-548n

0.0004

MYOG

0.0025

miR-27a-3p

0.0004

SP1

0.0067

miR-4650-5p 0.0005

SP7

0.0025

miR-215-5p

TP53

0.0016

0.0005

miR-143-3p

0.0007

ZBTB7B

0.0051

miR-9-5p

0.001

ZNF384

0.0051

Figure 3. Reconstructed tumor microenvironment generic network and hub biomolecules.
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Figure 4. Scenarios of interactions among mutual hub biomolecules in breast and ovarian tumor stroma. a) interaction of transcriptional
regulators and core DEG, b) interaction of transcriptional regulators and both hub protein in PPI network and core DEG, c) interaction
of transcriptional regulators and core DEG, d) interaction of transcriptional regulators and both hub protein in PPI network and core
DEG.

hub biomolecules using by GeneCards database (Safran et
al., 2010). It was suggested that these ten hub biomolecules
may be significant novel molecular signatures in stroma
targeted cancer treatment.
3.4. Potential prognostic targets in the tumor
microenvironment
Stromal content of TCGA datasets of breast and ovarian
cancer were identified via Estimation of STromal and
Immune cells in MAlignant Tumours using Expression
(ESTIMATE) data method. According to the results, the
relatively high stromal score was found in breast carcinoma
and high-grade serous ovarian carcinoma (Yoshihara et
al., 2013). Kaplan–Meier graphs for estimating the survival
curve, the log-rank test to compare two groups statistically
were used to determine the prognostic potential of hub
genes in the generic network. According to the analysis,
statistically significant results could be obtained for all
datasets (Figures 5a–5c). Furthermore, gene expression
profiles of the hub genes were represented via heat maps
(Figures 5d–5f). ESR1, TOR1AIP1, STAT1, COL1A1 were
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identified as high expression, while EGFR, AR, GATA2
were identified as a low expression in both cancer types.
Only GATA3 represented different expression profiles
including the high expression for breast cancer (Figure
5d) and low expression for ovarian cancer (Figures 5e and
5f). Kaplan–Meier graphs of hub miRNAs, miR-124 and
miR-192 were also represented (Figure 6). Although miR124 was identified as prognostic miRNAs for both cancer
type, miR-192 was determined as prognostic biomolecule
for only ovarian cancer, it was not obtained statistically
significant result for breast cancer. It was suggested that
hub biomolecules of the tumor microenvironment generic
network obtained from breast and ovarian cancer stroma
samples represent prognostic biomolecule potentials in
patients with breast and ovarian cancer.
4. Discussion
Understanding of the pathogenic mechanism and
molecular signatures of tumor stroma should provide
valuable insight into cancer initiation and progression. We
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Table 2. The biological importance and descriptions of hub biomolecules in the present study.
Hub
Biological importance
biomolecules
The protein function of AR is a steroid-hormone activated TF that affect proliferation and differentiation in target
AR
tissues.
GATA2

GATA2 is a TF involved in stem cell maintenance with important roles in hematopoietic development.

miR-124

Among its related pathways are MicroRNAs in cancer and Alzheimers Disease.

TOR1AIP1

The protein of this gene is responsible for nuclear membrane integrity.

ESR1

Nuclear hormone receptor. ESR1 is clinically relevant in breast, endometrial, ovarian and other cancer types.

EGFR

It is a transmembrane glycoprotein and its amplification and mutations have been shown to be driving events in
many cancer types.

STAT1

Signal transducer and TF that mediates cellular responses to interferons, cytokines and growth factors.

miR-192

Among its related pathways are MicroRNAs in cancer.

GATA3

GATA3 is a TF and an important regulator of T-cell development. It is required for the T-helper 2 differentiation
process in the immune response.

COL1A1

It is a fibril-forming collagen found in most connective tissues.

Figure 5. Prognostic potential of the hub biomolecules in the tumor microenvironment generic network. a) Kaplan–Meier plot for
breast cancer patients obtained from the TCGA database, b) Kaplan–Meier plot for ovarian cancer patients obtained from the ICGC
database, c) Kaplan–Meier plot for ovarian cancer patients obtained from the TCGA database. The p-values are computed via the longrank test (p < 0.05). Heat map represents the expression of hub genes (rows) along with samples (columns) in risk groups for d) breast
cancer samples, e) ovarian cancer samples obtained from ICGC database, f) ovarian cancer samples obtained from TCGA database.
The green and red grades represent the downregulated and upregulated expression, respectively. Two stars (**) marks genes represent
p-value <0.05 and no stars represent p-value is >0.05. The difference of gene expression between risk groups compare using a t-test were
presented by box plots.

studied differential gene expression in breast and ovarian
cancer stroma with the common regulatory patterns,
common key pathways, cancer stroma associated PPI and
tumor microenvironment generic network to identify
central molecular signatures that may serve as potential

prognostic or therapeutic targets in breast and ovarian
cancer. The difference of this study from other current
studies is to analyze the ovarian cancer stroma and breast
cancer stroma datasets separately, then to identify the
common molecular signatures, to determine the common
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Figure 6. Kaplan–Meier graphs of hub miRNAs in the tumor microenvironment generic network according to KM plotter tool
result (p < 0.05).

network structures and to discover some stromal features
that can guide the prognosis and treatment. These features
can give a holistic view of breast cancer stroma and
ovarian cancer stroma, as well as the hub biomolecules
obtained, which can be used as guiding target molecules
in prognostic and therapeutic applications.
Analyzing the gene expression patterns of each dataset
were enriched common pathways in immune systems
related pathways, signaling pathways, and stroma associated
pathways such as proteoglycan in cancer, collagen
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formation, extracellular matrix organizations. Moreover,
the core DEGs were enriched in different biological
processes and molecular functions such as binding and
catalytic activity. PPI network provides a comprehensive
framework for exploring the basic mechanisms behind
human disease (Sevimoglu and Arga, 2014). The cancer
stroma specific network was reconstructed by using
reporter receptors, regulatory reporter molecules, TFs
and miRNAs, interacted with target core DEGs (Table
1). Through a holistic approach, it was determined that
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hub biomolecules of tumor microenvironment generic
network and hub proteins of PPI network interact within
themselves. These hub biomolecules of tumor stroma
network, AR, GATA2, miR-124, TOR1AIP1, ESR1, EGFR,
STAT1, miR-192, GATA3, COL1A1, may give crucial
information about tumorigenesis (Table 2). Because
stroma associated cells and factors have a supportive
role in carcinogenesis they are expressed during cancer
initiation and progression (Bhowmick and Moses, 2005).
Thus, altered and highly interacted hub biomolecules
may provide key information on the dysregulation of
gene expression in the carcinogenesis of ovarian and
breast tissues. Moreover, the resultant biomolecules were
also identified as prognostic biomolecules in the tumor
samples.
Prognostic stroma-related genes were subject to
literature data mining in terms of association with tumor
stroma and malignancies. Henshall et al. (2001) reported
that AR expression in tumor epithelium and stroma that
is associated with a poor clinical outcome in prostate
cancer, on the other hand, AR is emerging as a potential
new therapeutic target for the treatment of breast cancer
(Giovannelli et al., 2018). Epidemiological and preclinical
studies have been made showing the crucial potential
involvement of AR signaling in ovarian tumorigenesis
(Mizushima and Miyamoto, 2019). GATA2 gene has
been identified in stroma-related studies in colon cancer
prognosis (Uddin et al., 2019), and also reported as
a molecular signature in ovarian cancer via network
medicine perspective (Gov et al., 2017). Wang et al. (2016)
reported that miR-124-3p is a tumor suppressor in breast
cancer. Various research has shown that miR‐124 may
act as a tumor suppressive by regulating different target
genes in several cancers such as prostate cancer (Shi et
al., 2013), and head and neck cancer (Zhao et al., 2017).
It is widely known that the use of inhibitors of ER (ESR1)
in the treatment of patients with estrogen-positive breast
cancer has offered a good prognosis (Tong et al., 2018).
Moreover, the ESR1 gene is frequently methylated in
many types of gynecological malignancies such as highly
expressed in epithelial ovarian cancer (Giannopoulou et
al., 2018). EGFR is the other well-known cancer-related
protein. Wang et al. (2016) recently reported that high

expression of EGFR in tumor stroma has a correlation
with aggressive clinical properties in epithelial ovarian
cancer, and is a prognostic factor. On the other hand,
that upregulated expression of EGFR protein has been
reported to occur in 16%–36% of breast cancers (Bhargava
et al., 2005). Zellmer et al. (2017) showed that STAT1
expression in stroma promotes tumor progression and it
is a potential target for breast cancer treatment. STAT1 is
a tumor suppressor gene in breast cancer (Koromilas and
Sexl, 2013) and upregulated STAT1 expression with better
response to chemotherapy in patients with ovarian cancer
(Josahkian et al., 2018). Hu et al. (2013) reported that miR192 expression is significantly downregulated in breast
cancer tissue and the miR-192/215 family is upregulated
in mucinous ovarian tumor samples (Agostini et al.,
2018). GATA3 takes a crucial role in normal mammary
gland development, and its expression demonstrates high
correlation with the estrogen receptor α (ERa) in human
breast tumors (Eeckhoute et al., 2007). Moreover, it was
showed that GATA3 expression is related to poor prognosis
of high-grade serous ovarian carcinoma patients (Chen et
al., 2018). Recently it was reported that COL1A1 secreted
by fibroblasts promoted stromal cells and facilitates the
metastasis of ovarian cancer, which may provide a novel
approach for ovarian cancer therapeutics (Li et al., 2020).
Considering the potential role of identified molecular
signatures in the tumor microenvironment, two
biomolecules, GATA2 and TORYAIP1, might be a novel
candidate for the treatment in the breast and ovarian
cancer. To the best of our knowledge there has been no
published report that explained they would be utilized
as a novel candidate for molecular signatures in tumor
stroma and the treatment of these cancers. We suggest
experimental studies to identify the possible role of these
proteins. The present study shares a novel approach
regarding the molecular mechanism and identification of
potential molecular signatures and candidate drug targets
for the stroma targeted cancer therapy applications.
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